Skip to main content
. 2018 Oct 4;68(7):1144–1151. doi: 10.1093/cid/ciy654

Table 3.

Adherence to and Acceptability of the Vaginal Ring by Study Arm

DPV (n = 72) Placebo (n = 24) All Arms (N = 96)
Adherence by self-report
 Week 4 58 (80.6%) 22 (91.7%) 80 (83.3%)
 Week 8 67 (93.1%) 22 (91.7%) 89 (92.7%)
 Week 12 65 (90.3%) 21 (87.5%) 86 (89.6%)
Median residual DPV levels in VR [IQR] NA NA
 Week 4 21.2 mg [20.8, 21.6]
 Week 8 21.1 mg [20.7, 21.5]
 Week 12 21.0 mg [20.6, 21.4]
Overall acceptability of the VRa,b n = 71 n = 22 n = 93
Dislike very much 0 0 ...
Dislike 6 (8.5%) 3 (14.6%) 9 (9.7%)
Like 38 (53.5%) 12 (54.6%) 50 (53.8%)
Like very much 27 (38.0%) 7 (31.8%) 34 (36.6%)
Preference for VR vs condomsb n = 69 n = 22 n = 91
Prefers VR 42 (60.9%) 17 (77.3%) 59 (64.8%)
Prefers condoms 6 (8.7%) 2 (9.1%) 8 (8.8%)
Likes both 19 (27.5%) 3 (13.6%) 22 (24.2%)
Likes neither 2 (2.9%) 0 (0%) 2 (2.2%)
Comfort with VRb n = 72 n = 22 n = 94
VR is very easy /easy to use 71 (98.6%) 22 (100%) 93 (98.9%)
Is very comfortable /comfortable with VR inside every day 70 (97.2%) 21 (95.5%) 91 (96.8%)
Agreed that VR is easy to insert 62 (86.1%) 18 (81.8%) 80 (85.1%)
Agreed that VR is easy to remove 58 (80.6%) 17 (77.3%) 75 (79.8%)

Abbreviations: DPV, dapivirine; IQR, interquartile range; NA, not applicable; VR, vaginal ring.

aMissing 1 answer.

bAsked by computer assisted self-interview at week 12.